Lantern Pharma Inc. LTRN

Lantern Pharma will host a live webinar today at 12:30 PM ET to outline Open-Medicine AI (OMAI), Lantern’s multi-agent AI platform for end-to-end drug development. CEO Panna Sharma will be joined by Lantern’s CSO and the platform’s Principal Architect. OMAI’s core capabilities were developed inside Lantern’s clinical programs and launched as withZeta.ai in April 2026 for rare cancers; it is expanding to additional diseases, therapies, and development stages. The session will cover market opportunity, customer usage and feedback, a real-time live demo, a roadmap with upcoming modules and milestones, subscription and enterprise licensing economics, performance benchmarks, and the types of collaborations and partnerships under discussion. A replay will be available after the event. Contacts for media and investor relations are provided. Highlights a strategic platform expansion and potential licensing revenue, which could moderately influence Lantern's growth trajectory.

Lantern Pharma announced that the USPTO issued a Notice of Allowance for US Patent Application 18/500,032, "Method for Treating Blood Cancers," covering LP‑284 use to treat mantle cell lymphoma (MCL) and double-hit lymphoma (DHL). Allowed claims include LP‑284 as a monotherapy and in combination with second anti-cancer agents such as DNA-damaging agents, glucocorticoids, IMiDs, BCL2 inhibitors, BTK inhibitors, spironolactone, PARP inhibitors, and proteasome inhibitors, as well as different routes of administration (intravenous, intraperitoneal). The patent, once issued, would extend LP‑284 protection into 2042 and complements the existing composition‑of‑matter rights through 2039 across major markets. Lantern notes LP‑284 already has three FDA Orphan Drug Designations (MCL, HGBL with MYC/BCL2 rearrangements, soft tissue sarcomas) and is in a Phase 1 trial (NCT06132503). Management says this strengthens the program's long-term commercial potential. Strengthens LP-284's long-term IP moat and commercial potential through a 2042 expiry with broad use-in-combination claims, elevating future value despite early-stage trials.

Lantern Pharma will present its Open-Medicine AI multi-agentic platform for end-to-end therapeutic development, covering business model, roadmap, and value proposition, on September 23. Presentation of core AI platform for drug development may moderately influence investor views on innovation and positioning.

Lantern Pharma Inc. (LTRN) held Q2 2026 earnings call covering financial results and company updates. Earnings call details financial performance and outlook that can affect stock sentiment.

Lantern Pharma Inc. (LTRN) highlighted progress in its AI-driven drug development pipeline during its Q2 2026 earnings call. AI-driven pipeline advances signal major strategic progress in drug development with potential to shift company trajectory.

Lantern Pharma Inc. released Q2 2026 earnings call summary covering quarterly results and outlook. Q2 2026 earnings call delivers financial and strategic updates that moderately influence company trajectory.

Lantern Pharma Inc. reported second quarter 2026 financial results and issued a business update. Quarterly financial results and business updates can moderately affect company valuation and investor sentiment.

Lantern Pharma establishes Open-Medicine AI as a separate company to commercialize and expand its Multi-Agent AI Co-Scientist Platform for transforming medicine. Spinning off the AI platform creates a dedicated vehicle for commercialization that can generate new revenue and strategic value for Lantern Pharma.

Lantern Pharma advances EMA-cleared Phase 1b/2 trial of LP-184 (Zirdafulven) in biomarker-selected advanced bladder cancer. EMA-cleared trial start for LP-184 in bladder cancer signals major clinical and regulatory progress that can shift company trajectory.

Lantern Pharma receives USPTO notice of allowance for patent on biomarker-guided LP-184 (Zirdafulven) treatment in multiple solid tumor cancers. Patent allowance bolsters IP protection for core drug candidate LP-184 and supports oncology pipeline value.

Lantern Pharma launches ZetaOmics™, an autonomous intelligent computational biologist delivering expert-grade bioinformatics, biostatistics and reasoning for cancer research. ZetaOmics launch introduces proprietary AI platform that strengthens Lantern Pharma's oncology drug development capabilities and competitive positioning.

Lantern Pharma reports HARMONIC trial data showing LP-300 progression-free survival benefit deepens with longer treatment duration in EGFR Exon 21 L858R lung cancer. Positive HARMONIC data on LP-300 strengthens Lantern Pharma's clinical pipeline and investor outlook in targeted lung cancer therapy.

Lantern Pharma Inc. released its Q1 2025 earnings transcript covering financial results, operational progress in oncology drug development, and forward-looking statements on clinical trials and capital allocation. Quarterly earnings updates deliver financial metrics and pipeline status that moderately shape investor views without triggering major strategic shifts.

Lantern Pharma secured successful FDA Type C meeting outcome supporting HARMONIC Phase 2 trial design for LP-300 in never-smokers with NSCLC. FDA alignment on Phase 2 trial advances LP-300 development and strengthens company trajectory in NSCLC.

Lantern Pharma reported first quarter 2026 financial results and business updates. Quarterly financial results and business updates typically influence near-term investor sentiment and valuation without fundamentally redefining long-term strategy.

Lantern Pharma Inc. closed a registered direct offering raising up to $9.25 million from existing holders and a single institutional investor. The $9.25 million capital raise funds key R&D and operations, significantly bolstering financial position and market sentiment.

Lantern Pharma Inc. announced a registered direct offering of up to $9.25 million, priced at-the-market under Nasdaq rules, with participation from existing holders and a single institutional investor, expecting $8.3 million in gross proceeds before fees. The up to $9.25 million funding bolsters Lantern Pharma's cash reserves for operations but introduces share dilution risks.

Lantern Pharma unveiled a roadmap for withZeta.ai, launching ZetaSwarm™ and ZetaOmics™ as the industry's first multi-agentic co-scientist featuring swarm intelligence and a computational biology toolkit. Launching an industry-first AI co-scientist with swarm intelligence and advanced toolkits marks a major strategic move enhancing Lantern Pharma's innovation and competitive edge in drug discovery.

Lantern Pharma evolves predictBBB.ai into a real-time Large Quantitative Model (LQM) for precision molecular intelligence, offering comprehensive small molecule characterization and development analytics as a web service to drug developers globally. Evolving predictBBB.ai into a scalable global web service unlocks new revenue potential and strengthens LTRN's position in AI-driven drug development.

Lantern Pharma Inc. (LTRN) issues correction inviting participation on April 30 for the first public demonstration of withZeta.ai, an AI platform designed to conquer rare cancers. First public demo of withZeta.ai platform for rare cancers signals major strategic tech advancement boosting LTRN's innovation profile and investor sentiment.

Lantern Pharma Inc. (LTRN) invites participation in the first public demonstration of withZeta.ai on April 30, a platform designed to conquer rare cancers. First public demo of AI platform for rare cancers signals major strategic product launch with potential to drive investor sentiment and market performance.

Lantern Pharma Inc. (LTRN) will publicly demonstrate its withZeta.ai platform, designed to conquer rare cancers, on April 30 following its scientific debut at AACR 2026. Public demo of AI platform targeting rare cancers after AACR scientific debut signals major strategic push in oncology innovation.

Lantern Pharma’s investigational drug LP-300 achieves 8.3-month median progression-free survival in EGFR L858R lung cancer patients after targeted therapy failure, with no added toxicity. Strong efficacy data for LP-300 in refractory lung cancer enhances pipeline value and investor sentiment for LTRN.

Lantern Pharma launches withZeta.ai, the world’s first multi-agentic AI co-scientist for rare cancer drug discovery and development. Subscriptions now open, with debut events at Nasdaq MarketSite on 4/16 and AACR 2026 from 4/17 to 4/22. Launch of world's first multi-agentic AI co-scientist for rare cancer drugs represents a major product innovation and revenue opportunity for LTRN.

Lantern Pharma Inc. (LTRN) Q4 2025 earnings call highlights strategic advances amid financial challenges. Strategic advances in earnings call represent major moves likely to alter trajectory and investor sentiment despite financial pressures.

Lantern Pharma Inc. (LTRN) invites investors, analysts, and shareholders to a live demo of withZeta.ai, the world's first multi-agentic co-scientist for rare cancers, on April 9, 2026, at 8:30 AM Eastern. Live demo of pioneering AI co-scientist for rare cancers represents a major strategic showcase likely to boost investor sentiment and competitive positioning in drug discovery.

Lantern Pharma Inc. (LTRN) reported fourth quarter and full-year 2025 financial results, alongside business updates. Financial results and business updates represent major strategic disclosures that can significantly alter investor sentiment and company trajectory.

Lantern Pharma and Starlight Therapeutics received FDA clearance for an IND to initiate a Phase 1 clinical trial of STAR-001 for pediatric central nervous system (CNS) cancers. FDA IND clearance enables Phase 1 trial initiation for STAR-001 in pediatric CNS cancer, advancing Lantern Pharma's oncology pipeline and boosting investor sentiment.

Lantern Pharma Inc. (LTRN) has made significant advancements in oncology AI, enhancing its capabilities in drug discovery and development. The company has also received orphan drug designation for its lead candidate, which is aimed at treating specific rare cancers. This recognition is expected to facilitate the development process and provide potential market exclusivity, further strengthening Lantern's position in the oncology sector. The advancements in AI and orphan drug recognition are likely to significantly impact Lantern Pharma's future performance and market positioning.

Lantern Pharma Inc. will present at the 7th Glioblastoma Drug Development Summit in Boston from February 17-19, 2026. The event focuses on advancements in glioblastoma treatments, providing a platform for discussions on drug development and innovation in this challenging area of oncology. Participation in a significant industry summit may enhance visibility and networking opportunities for Lantern Pharma.